http://www.biospectrumindia.com | July 2017 | BioSpectrum l SUPPLIER NEWS^17
Thermo Fisher Scientific, the world leader in serving science, launched
a new capillary electrophoresis (CE) system designed to offer a low-
throughput, cartridge-based system for Sanger sequencing and fragment
analysis.
For use with oncology research,
genome editing, species identification,
and human cell line authentication
among other common applications,
the Applied Biosystems SeqStudio
Genetic Analyzer supports the growing
need for an affordable and easy-to-use
CE platform.
The new SeqStudio Genetic Analyzer
utilizes a unique all-in-one cartridge that
combines the capillary array, polymer reservoir and anode buffer, which
vastly simplifies preparation and hands-on processing time.
Other innovative features of the system allow customers to access
individualized protocols, an intuitive touchscreen and connectivity to the
Thermo Fisher Cloud for remote setup and monitoring as well as easy data
analysis and collaboration.
The SeqStudio instrument has a small footprint, with an onboard
computer and integrated touchscreen that makes run setup quick, intuitive
and flexible. The system allows sequencing and fragment analysis runs on
the same plate without the need to change any consumables. This opens new
opportunities for streamlining analyses – for example, combining a locus
screening test with a copy number variability test on the same CE plate.
Bosch launched a new pilot
fermenter for the cultivation of
active pharmaceutical ingredients
(APIs) on laboratory and pilot scale.
In the pharmaceutical industry, the
manufacture of complex compounds
using biotechnological methods
continues to grow in importance.
Whether the desired substance is an
insulin preparation or a medication
for targeted cancer therapy, the
bioprocessing systems at Bosch
deliver optimum product quality
and excellent process results. The
pilot fermenter was presented at
interpack 2017 in Duesseldorf.
When it comes to designing
fermentation systems, the goal
is to create optimal growing
conditions for microorganisms
such as cells and bacteria. At the
same time, these systems have to
meet the strict cGMP regulation
standards for the pharmaceutical
industry. Bosch’s highly versatile
pilot fermenter satisfies the specific
requirements for the production
of APIs, and for a diverse range of
applications.
Depending on requirements, the
system can be equipped with one
of several interchangeable mixing
elements, designed for different
cell types and process controls. The
mixer regulates the inflow of liquids
or gases needed for cell cultivation.
Sensitive cells require the use of
gentler technologies like the air lift
module, while more robust cells
can be stirred mechanically.QIAGEN has received a
worldwide license from The
Johns Hopkins University for
biomarkers that have been
shown to play key roles in
identifying patients who could
benefit from novel immune-
oncology (I-O) therapies in
cancer treatment.
The agreement involves
rights to genetic biomarkers to
assess microsatellite instability
(MSI) and mismatch repair
(MMR) in all sample and cell
types, and will enable QIAGEN
to commercialize molecular
testing solutions using next-
generation sequencing to assess
MSI and MMR status. Levels of
MSI and MMR, along with tumor
mutation burden (TMB), are
important in identifying cancer
patients who could benefit from
certain types of I-O therapies,
which offer a novel way to treat
cancer by using drugs to target
the body’s immune system to
help fight cancer.
QIAGEN reached this
agreement prior to the U.S.
Food and Drug Administration’s
(FDA) approving in May 2017
an I-O therapy to treat advanced
solid tumors with MSI and MMR
deficiencies, marking the first
time that the FDA has cleared
a cancer drug for use not tied to
the site of a tumor. The Johns
Hopkins University has been
at the forefront of research in
linking MMR defects to cancer.Qiagen
expands biomarker
content portfolioThermo Fisher Scientific introduces
latest in Capillary Electrophoresis
Bosch launches
new pilot fermenter